Human cohorts link higher NT-proBNP with mortality and lower grip strength, and with incident frailty in people without known cardiovascular disease at baseline. A human trial reports decreases with empagliflozin in heart failure with reduced ejection fraction and diabetes or prediabetes, while another shows no clear effect with cholecalciferol in older adults with low vitamin D levels.
324 findings in 250 papers from 2007 to 2026, 95 of them since April 2026
“those with lower Ca2+ (Q1, mean 2.2 ± 0.1 mmol/L) presented more peripheral edema and higher NT-proBNP levels (P < 0.05).”
SGLT2 inhibitors decrease NT-proBNP in humans (post-ACS diabetic patients, SGLT2i group vs control, at 3 months) (5541.6±8443.5 to 1179.6±1644.6 pg/ml).
“NT-proBNP decreased markedly in the SGLT2i group (5541.6±8443.5 to 1179.6±1644.6 pg/ml, p=0.004)”
Human trialpost-ACS diabetic patients, SGLT2i group vs control, at 3 months3 monthsn = 25
SGLT2 inhibitors decrease NT-proBNP in humans (HFpEF; before-and-after comparison without a control group) (Median 176.5 pg/mL vs 683 pg/mL at baseline; p ≤0.001).
“After six months, the NT-proBNP levels significantly decreased”
Human trialHFpEF; before-and-after comparison without a control group10 mg/day6 months82% femalesn = 100
SGLT2 inhibitors are linked with lower NT-proBNP in humans (patients with cardiac amyloidosis (AL and ATTR)) (MD –464.68 pg/mL; 95% CI –712.22 to –217.15).
“NT-proBNP levels (MD: –464.68 pg/mL; 95% CI –712.22 to –217.15; p = 0.0002)”
Humanspatients with cardiac amyloidosis (AL and ATTR)
Dapagliflozin decreases NT-proBNP in humans (Hospitalized acute heart failure; compared with acetazolamide alongside standard care) (−34.2% vs. −25.0%; P = 0.003).
“Dapagliflozin achieved a larger reduction in N‐terminal pro‐B‐type natriuretic peptide at 72 hours (−34.2% vs. −25.0%; P = 0.003).”
Human trialHospitalized acute heart failure; compared with acetazolamide alongside standard care10 mg once daily72 hoursn = 108
Dapagliflozin increases NT-proBNP in humans (type 2 diabetes without heart failure, on metformin monotherapy at recruitment) (+20% from baseline; p=0.07).
“whereas it increased by 20% in the dapagliflozin group (p=0.07).”
Human trialtype 2 diabetes without heart failure, on metformin monotherapy at recruitmentplasma6 monthsn = 92
Dapagliflozin decreases NT-proBNP in humans (-142 pg/mL (95% CI -324 to 41)).
“The estimated intervention-versus-baseline difference was −142 pg/mL (95% CI −324–41) for NT-proBNP, 24.3 m (95% CI −2.8 to 51.5) for 6MWT distance, and 0.4 points (95% CI −4.0 to 4.8) for KCCQ-TSS.”
Dapagliflozin is linked with lower NT-proBNP in humans during doxorubicin therapy in breast cancer patients with type 2 diabetes (+57.000 [95% CI +28.302, +85.698]).
“lower NT-proBNP levels (+ 57.000 [95% CI + 28.302, + 85.698]) compared with the non-dapagliflozin group (p < 0.001)”
Humansduring doxorubicin therapy in breast cancer patients with type 2 diabetes3 monthsn = 60
Empagliflozin is linked with lower NT-proBNP in humans (type 2 diabetes and acute decompensated heart failure; compared with basal-bolus insulin) (1699 ± 522 vs. 2303 ± 598 pg/ml at discharge).
“the N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were lower in the empagliflozin continuation group than in the insulin group”
Humanstype 2 diabetes and acute decompensated heart failure; compared with basal-bolus insulincombined with basal insulin regimenduring hospitalization
Sacubitril + valsartan decreases NT-proBNP in humans after switching from azilsartan (-18.3 ± 25.5%).
“Sacubitril/valsartan treatment decreased BP, morning‐to‐nighttime decrease in home SBP, body mass index, body weight, and NT‐proBNP level, whereas other variables such as potassium and estimated glomerular filtration rate did not change significantly.”
Human trialafter switching from azilsartan6 monthsn = 27
Journal of clinical hypertension (Greenwich, Conn.)·
Sacubitril + valsartan decreases NT-proBNP in humans (heart failure with reduced ejection fraction).
“we observed a significant improvement in humoral and functional parameters of CGA, renal function, NTpro-BNP levels and echocardiographic parameters.”
Human trialheart failure with reduced ejection fraction6 monthsn = 61
American journal of cardiovascular drugs : drugs, devices, and other interventions·
Nicotinamide adenine dinucleotide showed no clear effect on NT-proBNP in humans (1471.00 [828.00–2950.00]pg/mL vs. 2317.50 [1155.00–4752.50]pg/mL).
“As presented in Table, there was a trend towards reduced levels of NT-proBNP in the NAD+ group at 7 days (1471.00 [828.00–2950.00]pg/mL vs. 2317.50 [1155.00–4752.50]pg/mL, p = 0.102].”
Exercise decreases NT-proBNP in humans (chronic heart failure).
“after the intervention, NT-proBNP levels and MLHFQ scores in the rehabilitation group were both lower than before the intervention and lower than those in the control group (P<0.05)”
Coenzyme Q10 + selenium decreases NT-proBNP in humans.
“Equally, in the male group at 48 months, a higher value in the placebo group compared with the active treatment group was noted (F(1,98)= 4.20; p = 0.04).”
Coenzyme Q10 + selenium decreases NT-proBNP in humans (214 ng/L vs. 302 ng/L at 48 months (P=0.014)).
“NT-proBNP levels were significantly lower in the active group compared with the placebo group (mean values: 214 ng/L vs. 302 ng/L at 48 months; P=0.014).”
Plant-based meat-supplemented diet increases NT-proBNP in humans (+ 0.19log units, 95%CI + 0.04 to + 0.35).
“The plant-based sequence was associated with significant increase in weight (+ 0.6 kg, 95%CI + 0.1 to + 1.0, P = 0.012); and NTproBNP (57 (27–148)pg/mL vs 54 (16–106)pg/mL, + 0.19log units, 95%CI + 0.04 to + 0.35; P = 0.013).”
Hypercaloric, hyperproteic oral supplement decreases NT-proBNP in humans (plus Mediterranean diet) (decreased by 1303 pg/mL (741–2111) after 24 weeks).
“In particular, the intervention group (1952 pg/mL (1179–3307 at baseline) decreased by 1303 pg/mL (741–2111) after 24 weeks (p = 0.02). Although NT-proBNP also decreased in the control group, this change was not statistically significant.”
Human trialplus Mediterranean diettwenty-four weeksn = 19
Sauna bathing increases NT-proBNP in humans (+12.00%).
“Overall NT-proBNP levels were 46.0 ng/L before sauna exposure, which increased to 50.5 ng/L immediately after sauna (median percentage change, 12.00%; p < 0.001).”
Sauna bathing increases NT-proBNP in humans (+12.00%, p < 0.001).
“Overall median N-terminal pro-B-type natriuretic peptide (NT-proBNP) level (n = 20 participants) was 46.0 ng/L before sauna exposure, which increased to 50.5 ng/l immediately after sauna (median change, + 12.00%; p < 0.001)”
NT-proBNP was not clearly linked with mortality in humans (NT-proBNP concentration above 1099 ng/L).
“When the NT-proBNP concentration was above 1099 ng/L, the mortality did not increase anymore when NT-proBNP increased (OR=1.00, 95%CI: 0.99-1.02, P=0. 7786).”
NT-proBNP was not clearly linked with mortality in humans (geriatric hip fracture, preoperative NT-proBNP > 781 ng/L) (HR 1.00, 95% CI 0.98-1.01, P = 0.4718).
“whereas at > 781 ng/L, NT-proBNP was not associated with mortality (HR = 1.00, 95% CI: 0.98-1.01, P = 0.4718).”
Humansgeriatric hip fracture, preoperative NT-proBNP > 781 ng/Lserumn = 1,354
NT-proBNP is linked with better SCORE2 discrimination in humans (Addition to SCORE2) (C-index 0.748 (95% CI 0.729–0.766) to 0.780 (95% CI 0.762–0.798)).
“Addition of NT-proBNP increased discrimination to 0.780 (95% CI 0.762–0.798)”
NT-proBNP was not clearly linked with sarcopenia in humans (high NT-proBNP levels; community-dwelling older adults) (OR 1.45 (95% CI 0.53-4.01) for sarcopenia).
“high NT-proBNP levels were not significantly associated with low SMI (OR: 1.34, 95% CI: 0.54-3.32), handgrip strength (OR: 1.32, 95% CI: 0.65-2.34), or sarcopenia (OR: 1.45, 95% CI: 0.53-4.01).”
NT-proBNP is linked with lower symptomatic alleviation in humans after T-TEER for tricuspid regurgitation (adjusted OR per log10 increase: 0.63; 95% CI: 0.48-0.84; P < 0.001).
“higher NT-proBNP was associated with a lower likelihood of symptomatic alleviation (adjusted OR per log10 increase: 0.63; 95% CI: 0.48-0.84; P < 0.001).”
Humansafter T-TEER for tricuspid regurgitationn = 2,282
NT-proBNP improves heart failure diagnosis in humans.
“biomarkers, particularly natriuretic peptides such as N-terminal prohormone of BNP (NT-proBNP), are central to early HF detection, showing high sensitivity.”
“NT-proBNP, high-sensitivity C-reactive protein, and high-sensitivity cardiac troponin T are highlighted for their potential to enhance risk prediction and clinical management.”
Testosterone-to-estradiol ratio was not clearly linked with NT-proBNP in humans (postmenopausal women with HFpEF; adjusted for baseline NT-proBNP) (β=0.114, P=0.212).
“baseline T/E2 was not associated with 12-month NT-proBNP (β=0.114, P=0.212)”
Humanspostmenopausal women with HFpEF; adjusted for baseline NT-proBNP12 monthsfemalesn = 184
Left ventricular end-diastolic wall stress is linked with NT-proBNP in humans (without heart failure) (mediation effect: 0.0028; 95% CI: 0.0006-0.0055).
“The association of BMI and NT-proBNP was partially mediated by DWS (mediation effect: 0.0028; 95% CI: 0.0006-0.0055) but not SWS (mediation effect: -0.0006; 95% CI: -0.0032 to 0.0015).”
Older age is linked with higher NT-proBNP in individuals without previous cardiovascular disease (rising from 1.4% (<30y) to 81.0% (≥80y) in males, and 9.8% (<30y) to 76.5% (≥80y) in females).
“At age <30 years, 9.8% of females and 1.4% of males had elevated NT-proBNP, rising to 76.5% and 81.0%, respectively, at age ≥80 years.”
Humansin individuals without previous cardiovascular diseasen = 18,356
NT-proBNP is associated with mortality in humans (HR 1.68, 95% CI 1.19–2.37).
“high versus low NT-proBNP was associated with a 1.68-fold higher mortality hazard”
HumansFrail cancer patients hospitalized with established anticancer treatment-related cardiac dysfunction/heart failure; high versus low NT-proBNP using cohort median 4562 pg/mLMedian follow-up 28 monthsn = 399
NT-proBNP is linked with a higher risk of mortality in humans (heart failure) (HR 1.76, 95% CI 1.30-2.38).
“high NT-proBNP (HR:1.76; 95%CI 1.30-2.38) and HF readmissions within 1 year (HR:2.68; 95%CI 1.72-4.16) remained independently associated with mortality.”
NT-proBNP is associated with mortality in humans (increasing NT-proBNP (change ≥+25%) compared with no change) (HR 1.73 (95% CI 1.37-2.17)).
“multivariable-adjusted HRs in the increasing group were 1.73 (95% CI 1.37-2.17), 1.76 (95% CI 1.08-2.87), and 1.71 (95% CI 1.32-2.22) for all-cause, cardiovascular, and non-cardiovascular mortality”
Humansincreasing NT-proBNP (change ≥+25%) compared with no changeserum10.3 yearsn = 2,703
NT-proBNP is associated with mortality in humans (Clinically stable, asymptomatic hemodialysis patients; irrespective of galectin-3 levels) (Adjusted hazard ratios 2.58 and 1.93 versus the reference group).
“Higher NT-proBNP levels were associated with increased all-cause mortality, irrespective of galectin-3 levels”
NT-proBNP is linked with a higher risk of mortality in humans (hip fracture surgery, high vs low NT-proBNP) (adjusted HR 2.66 (95% CI 1.63-4.32)).
“the adjusted hazard ratio for 2-year all-cause mortality was 1.51 (95% CI 0.91-2.50) for those in the moderate NT-proBNP group and 2.66 (95% CI 1.63-4.32) for those in the high NT-proBNP group”
Humanship fracture surgery, high vs low NT-proBNP2-yearn = 2,595
NT-proBNP is linked with a higher risk of heart failure in humans with LVH and highest biomarker tertile vs low biomarker levels without LVH (HR: 3.78; 95% CI: 2.78 to 5.15).
“Adjusted risk of HF (N = 643 events) was approximately 3.8-fold higher among participants with LVH and in the highest biomarker tertile, compared with those with low biomarker levels without LVH (NT-proBNP, hazard ratio [HR]: 3.78; 95% confidence interval [CI]: 2.78 to 5.15”
Humanswith LVH and highest biomarker tertile vs low biomarker levels without LVH
NT-proBNP is linked with a higher risk of frailty in humans (hospitalized patients with chronic heart failure) (incidence of frailty 68.75%).
“Multivariable logistic regression analysis showed that age, self-care ability, nutritional risk, Kinesiophobia and NT-proBNP were risk factors for frailty”
Humanshospitalized patients with chronic heart failuren = 256
NT-proBNP is linked with a higher risk of frailty in humans (without known CVD at baseline, NT-proBNP ≥300 pg/ml vs. <300 pg/ml) (HR 2.61 (95% CI: 1.28-5.33, P = 0.008)).
“(HRs) of 2.13 (95% confidence interval (CI): 1.130-4.01, P = 0.020) and 2.61 (95% CI: 1.28-5.33, P = 0.008), respectively.”
Humanswithout known CVD at baseline, NT-proBNP ≥300 pg/ml vs. <300 pg/mlplasmamedian follow-up of 21.7 yearsn = 5,199
Age is associated with NT-proBNP in people living with HIV (aOR 1.10 per 1-year increase, 95% CI 1.04-1.15, p = 0.0004).
“In multivariable analysis, older age was independently associated with elevated NT-proBNP (adjusted odds ratio [aOR] per 1-year increase: 1.10; 95% CI: 1.04-1.15; p = 0.0004)”
Atrial fibrillation is associated with NT-proBNP in humans.
“older age (80s and 90s), coronary artery disease, atrial fibrillation, and renal dysfunction were significantly associated with NT-proBNP ≥ 300 pg/mL”
NT-proBNP is associated with major adverse cardiovascular events in humans (Type 2 diabetes; elevated versus non-elevated baseline NT-proBNP) (aHR 1.34, 95% CI 1.10-1.64).
“Elevated (vs. non-elevated) NT-proBNP at baseline was associated with a higher risk of MACE (aHR 1.34, 95% CI 1.10-1.64)”
HumansType 2 diabetes; elevated versus non-elevated baseline NT-proBNPMedian follow-up of 9.1 yearsn = 3,326
NT-proBNP is associated with major adverse cardiovascular events in humans (Preoperative NT-proBNP >450 pg/mL; after osteoporotic hip fracture repair surgery).
“only preoperative RBCT, creatinine >1 mg/dL and NT-proBNP >450 pg/mL remained as independent preoperative risks factors for postoperative MACE”
HumansPreoperative NT-proBNP >450 pg/mL; after osteoporotic hip fracture repair surgery30 days after surgeryn = 140
NT-proBNP predicts cardiovascular mortality in humans (symptoms associated with HF) (approximately 200 pmol/L).
“Based on cardiovascular mortality, decision limits for BNP (approximately 50 pmol/L, approximately 170 ng/L) and Nt-proBNP ( approximately 200 pmol/L, approximately 1700 ng/L) (population II) were determined.”
Clinica chimica acta; international journal of clinical chemistry·
SGLT2 inhibitors
↓downin humans3
3 studies
SGLT2 inhibitors are associated with NT-proBNP in humans (hemodynamically stable patients with acute pulmonary embolism) (158 (96–443) vs. 1000 (333–3433) pg/mL; p < 0.001).
“lower N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, [158 (96–443) vs. 1000 (333–3433), 95% CI (467–1153) pg/mL, p < 0.001]”
Humanshemodynamically stable patients with acute pulmonary embolism
SGLT2 inhibitors are associated with NT-proBNP in humans (systemic right ventricle and heart failure) (31% reduction; adjusted geometric mean 796 to 550 ng/L; exp(β) 0.69, 95% CI 0.58–0.83).
“the adjusted geometric mean NT-proBNP value decreased from 796 to 550 ng/L under SGLT2i, corresponding to a 31% reduction”
Humanssystemic right ventricle and heart failure12 months after versus 12 months before initiation
SGLT2 inhibitors are associated with NT-proBNP in humans (heart failure with preserved ejection fraction) (347 [134.8–524.8] vs. 257 [161.3–427.5] pg/mL).
Cardiac rehabilitation is associated with NT-proBNP in humans (Myocardial infarction with systolic dysfunction) (2154 [1063.5-3796.5] pg/mL before Phase 2; 375.5 [195.75-624.5] pg/mL after Phase 2; 342.5 [170.25-661] pg/mL at one year).
“NTproBNP levels decreased significantly from 2154 [1063.5-3796.5] pg/mL before Phase 2 to 375.5 [195.75-624.5] pg/mL after Phase 2”
HumansMyocardial infarction with systolic dysfunctionOne year after myocardial infarction80.5% malessn = 87
Cardiac rehabilitation is associated with NT-proBNP in humans (heart failure; available admission and discharge measurements) (2130 pg/mL (IQR 1060–3710) at admission; 1570 pg/mL (IQR 937–2770) at discharge where available).
Cardiac rehabilitation is associated with NT-proBNP in humans (subset of patients with clinically stable heart failure with reduced ejection fraction).
“Mean NT-proBNP decreased (p < 0.01).”
Humanssubset of patients with clinically stable heart failure with reduced ejection fractioninpatient22.8-day inpatient stay
C-reactive protein is associated with NT-proBNP in humans (heart failure, 12-week titration with beta-blockers) (low-high +30 pg/ml vs high-low -8 pg/ml, P = 0.011).
“NT-proBNP changes were significantly different between the four hs-CRP groups (P = 0.011).”
Human trialheart failure, 12-week titration with beta-blockers12-weekn = 488
NT-proBNP is associated with peak oxygen consumption in humans (new-onset HFrEF) (β = -1.11 (95% CI: -2.15 to -0.06, p = 0.039)).
“reductions in N-terminal pro-B-type natriuretic peptide (NT-proBNP) and body mass index (BMI) were associated with higher pVO2 (β = -1.11 [95% CI: -2.15 to -0.06, p = 0.039]”
Human cohorts associate higher NT-proBNP with mortality, frailty, sarcopenia and cardiovascular events. Trials in people with heart failure report NT-proBNP reductions with SGLT2 inhibitors, while a henagliflozin trial reports no change.
In humans, NT-proBNP is associated with mortality and an increased risk of heart failure hospitalization. In male rats, aerobic treadmill training decreases cardiac NT-proBNP levels in both healthy and diabetic animals.
Median survival was 14.6% lower in artery-disease-prone mice lacking the proteins in blood-vessel-lining cells than in comparison mice.Median survival was 14.6% lower in artery-disease-prone mice lacking the proteins in blood-vessel-lining cells than in comparison mice.